Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
复制标题
DOI：
10.1038/sj.bjc.6600072
复制
发表时间：
2002-02-01
影响因子：
8.8
通讯作者：
van Diest, P
中科院分区：
文献类型：
--
作者：
Michalides, R;van Tinteren, H;Balkenende, A;Vermorken, J B;Benraadt, J;Huldij, J;van Diest, P
G1-S 调节因子细胞周期蛋白 D1 或细胞周期蛋白 A 的过度表达经常在乳腺癌中观察到，并且还会导致体外雌激素受体的配体依赖性激活。因此，这可能提供了他莫昔芬治疗失败的机制。我们通过免疫组织化学染色检查了这些以及其他细胞周期调节剂的失调对 394 名早期乳腺癌患者的他莫昔芬治疗的影响。在单变量分析中，cyclin A、Neu、Ki-67 指数的表达以及 OR 表达的缺乏与较差的预后显着相关。当通过临床模型（淋巴结状态、年龄、体能状态、T分类、分级、既往手术、雌激素受体状态和他莫昔芬使用）进行调整时，只有细胞周期蛋白A和Neu的过度表达与较差的预后显着相关，风险比分别为1.709（P=0.0195）和1.884（P=0.0151）。在接受他莫昔芬治疗的 201 例 OR 阳性病例中，有 86 例发现细胞周期蛋白 A 过度表达，并且是与较差预后相关的唯一独立标志物（风险比 2.024，P=0.0462）。总之，细胞周期蛋白 A 是早期乳腺癌复发的独立预测因子，因此也是接受他莫昔芬治疗的患者反应的标志物。英国癌症杂志 (2002) 86, 402–408。 DOI：10.1038/sj/bjc/6600072 www.bjcancer.com © 2002 癌症研究运动
Overexpression of G1-S regulators cyclin D1 or cyclin A is frequently observed in breast cancer and is also to result in ligand-independent activation of oestrogen receptor in vitro. This might therefore, provide a mechanism for failure of tamoxifen treatment. We examined by immunohistochemical staining the effect of deregulation of these, and other cell cycle regulators on tamoxifen treatment in a group of 394 patients with early stage breast cancer. In univariate analysis, expression of cyclin A, Neu, Ki-67 index, and lack of OR expression were significantly associated with worse prognosis. When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with hazard ratios of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151). Overexpression of cyclin A was found in 86 out of the 201 OR-positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio 2.024, P=0.0462). In conclusion, cyclin A is an independent predictor of recurrence of early stage breast cancer and is as such a marker for response in patients treated with tamoxifen. British Journal of Cancer (2002) 86, 402–408. DOI: 10.1038/sj/bjc/6600072 www.bjcancer.com © 2002 The Cancer Research Campaign